Literature DB >> 26702990

Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.

Carla Sini1, Claudio Fiorino2, Lucia Perna2, Barbara Noris Chiorda3, Chiara Lucrezia Deantoni3, Marco Bianchi4, Vincenzo Sacco3, Alberto Briganti4, Francesco Montorsi4, Riccardo Calandrino2, Nadia Di Muzio3, Cesare Cozzarini3.   

Abstract

PURPOSE: To prospectively identify clinical/dosimetric predictors of acute/late hematologic toxicity (HT) in chemo-naÏve patients treated with whole-pelvis radiotherapy (WPRT) for prostate cancer.
MATERIAL AND METHODS: Data of 121 patients treated with adjuvant/salvage WPRT were analyzed (static-field IMRT n=19; VMAT/Rapidarc n=57; Tomotherapy n=45). Pelvic bone marrow (BM) was delineated as ilium (IL), lumbosacral, lower and whole pelvis (WP), and the relative DVHs were calculated. HT was graded both according to CTCAE v4.03 and as variation in percentage relative to baseline. Logistic regression was used to analyze association between HT and clinical/DVHs factors.
RESULTS: Significant differences (p<0.005) in the DVH of BM volumes between different techniques were found: Tomotherapy was associated with larger volumes receiving low doses (3-20 Gy) and smaller receiving 40-50 Gy. Lower baseline absolute values of WBC, neutrophils and lymphocytes (ALC) predicted acute/late HT (p ⩽ 0.001). Higher BM V40 was associated with higher risk of acute Grade3 (OR=1.018) or late Grade2 lymphopenia (OR=1.005). Two models predicting lymphopenia were developed, both including baseline ALC, and BM WP-V40 (AUC=0.73) and IL-V40+smoking (AUC=0.904) for acute/late respectively.
CONCLUSIONS: Specific regions of pelvic BM predicting acute/late lymphopenia, a risk factor for viral infections, were identified. The 2-variable models including specific constraints to BM may help reduce HT.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bone marrow; Hematologic toxicity; Intensity-modulated radiotherapy; Prostate cancer

Mesh:

Year:  2015        PMID: 26702990     DOI: 10.1016/j.radonc.2015.11.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

1.  Lack of Relevant Haemogram Changes During Percutaneous Radiotherapy of Localised Prostate Cancer.

Authors:  Felix Zwicker; Benedict Swartman; Peter E Huber; Klaus Herfarth; Jürgen Debus; Henrik Hauswald
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.

Authors:  Pierfrancesco Franco; Francesca Arcadipane; Riccardo Ragona; Adriana Lesca; Elena Gallio; Massimiliano Mistrangelo; Paola Cassoni; Vincenzo Arena; Sara Bustreo; Riccardo Faletti; Nadia Rondi; Mario Morino; Umberto Ricardi
Journal:  Med Oncol       Date:  2016-06-08       Impact factor: 3.064

3.  Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial.

Authors:  Casey W Williamson; Igor Sirák; Ronghui Xu; Lorraine Portelance; Lichun Wei; Rafal Tarnawski; Umesh Mahantshetty; Elena S Heide; Catheryn M Yashar; Michael T McHale; Walter Bosch; Jessica Lowenstein; Cheryl C Saenz; Steve Plaxe; Ramez Eskander; John Einck; Arno J Mundt; Jyoti Mayadev; Loren K Mell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-20       Impact factor: 7.038

Review 4.  Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature.

Authors:  Haval Norman; Kimberley T Lee; Vered Stearns; Sara R Alcorn; Neha S Mangini
Journal:  Clin Breast Cancer       Date:  2021-07-27       Impact factor: 3.225

5.  Redefine the Role of Proton Beam Therapy for the Locally-Advanced Non-Small Cell Lung Cancer Assisting the Reduction of Acute Hematologic Toxicity.

Authors:  Xi Cao; Peilin Liu; Xian-Shu Gao; Shiyu Shang; Jiayu Liu; Zishen Wang; Mengmeng Su; Xuanfeng Ding
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

6.  Modulation of Peripheral Immune Cell Subpopulations After RapidArc/Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: Findings and Comparison With 3D Conformal/Conventional Fractionation Treatment.

Authors:  Fiorella D'Auria; Teodora Statuto; Luciana Rago; Antonietta Montagna; Giovanni Castaldo; Irene Schirò; Anna Zeccola; Teresa Virgilio; Gabriella Bianchino; Antonio Traficante; Alessandro Sgambato; Vincenzo Fusco; Luciana Valvano; Giovanni Calice
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

7.  Spleen Dose-Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer.

Authors:  Tetsuo Saito; Ryo Toya; Naoya Yoshida; Takashi Shono; Tomohiko Matsuyama; Satoshi Ninomura; Takahiro Watakabe; Yutaka Sasaki; Hideo Baba; Natsuo Oya
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

8.  Dosimetric Predictors of Treatment-related Lymphopenia induced by Palliative Radiotherapy: Predictive Ability of Dose-volume Parameters based on Body Surface Contour.

Authors:  Tetsuo Saito; Ryo Toya; Tomohiko Matsuyama; Akiko Semba; Natsuo Oya
Journal:  Radiol Oncol       Date:  2016-10-13       Impact factor: 2.991

9.  Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma.

Authors:  Sangjoon Park; Hwa Kyung Byun; Jinsil Seong
Journal:  Liver Cancer       Date:  2019-06-21       Impact factor: 11.740

10.  Immune correlates of therapy outcomes in women with cervical cancer treated with chemoradiotherapy: A systematic review.

Authors:  David S Lakomy; Juliana Wu; Dorothy Lombe; Emmanouil Papasavvas; Susan Citonje Msadabwe; Yimin Geng; Luis J Montaner; Elizabeth Chiao; Lilie L Lin
Journal:  Cancer Med       Date:  2021-06-12       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.